Greenwich Biosciences Revenue and Competitors

Claim your profile

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Greenwich Biosciences's estimated annual revenue is currently $245.4M per year.(i)
  • Greenwich Biosciences's estimated revenue per employee is $201,000

Employee Data

  • Greenwich Biosciences has 1221 Employees.(i)
  • Greenwich Biosciences grew their employee count by -5% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$54.7M27235%N/AN/A
#2
$1.2M6N/AN/AN/A
#3
$26.3M1313%N/AN/A
#4
$35M1240%$62.5MN/A
#5
$21.9M10910%N/AN/A
#6
$137.5M684-4%N/AN/A
#7
$14.9M8616%$173MN/A
#8
$91.3M454N/AN/AN/A
#9
$64.5M321-7%N/AN/A
#10
$9.4M470%N/AN/A

Greenwich Biosciences' vision is to make a positive difference in the lives of patients through the development of a portfolio of cannabinoid prescription medicines in a wide range of therapeutic indications. Our strategy is to build on our world leading position in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates. Epidiolex is Greenwich's lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. Greenwich's Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS). We have made a commitment to establish a fully integrated US operation to commercialize the product, with our US headquarters in Carlsbad, CA. Our Parent company (GW Pharmaceuticals, PLC), was founded in 1998 and is based in the UK. We are continuing to build out our team and are looking for talented individuals dedicated to making a difference in the lives of our patients.

keywords:N/A

N/A

Total Funding

1221

Number of Employees

$245.4M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Greenwich Biosciences News

2022-04-20 - Medical Cannabis Market 2022: Global Industry Analysis By ...

... Apothecanna, Zenabis Global Ltd, Cresco Labs, IDT Australia, MEDIFARM, Greenwich Biosciences, Inc., MediPharm Labs Inc., THC Global Group Limited,...

2022-04-19 - Medical Cannabis Market Analysis, Geographical ...

... IDT Australia, MEDIFARM, Greenwich Biosciences, Inc., MediPharm Labs Inc., THC Global Group Limited, Seed Cellar, CANNABIS SEEDS USA,...

2022-03-30 - A lot of interest': How South Florida keeps luring out-of-state ...

ICON International: Based in Greenwich, Connecticut, ... Pherros Biosciences: A new biotech company that will develop and produce novel...

2019-09-05 - Cannabidiol Market insights offered in a recent report

GW Pharmaceutical plc and Greenwich Biosciences, GW's subsidiary announced FDA's approval of EPIDIOLEX® cannabidiol oral solution in ...

2019-09-04 - GW Pharmaceuticals to Present at the Morgan Stanley 17th ...

04, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$839.2M153425%N/A
#2
$674.4M17841%N/A
#3
$621.9M195714%N/A
#4
$825.2M2147-3%N/A
#5
$1132.8M35500%N/A